Latest news with #Avance
UPI
5 days ago
- Business
- UPI
New ship is latest in series serving Central America, Caribbean basin
Crowley's fourth Advance-class LNG-powered ship, the Torogoz, launched on Aug. 12, 2025 from Port Everglades, Fla. The Torogoz is part of the shipping company's goal of providing more reliable service to Central America. Photo by Crowley Aug. 12 (UPI) -- U.S. maritime shipping company Crowley has launched the Torogoz, the final container ship in the company's Avance series of vessels that are intended to quickly move consumer items between the United States and Central America. The Torogoz departed from Port Everglades, Fla., on Tuesday for its first commercial voyage to Central America, the company announced. Like other ships in the Avance class, the Torogoz is powered by liquified natural gas, a fuel with lower greenhouse gas emissions. The ship's launch is a milestone for the company's goal of reliably delivering large amounts of dry and chilled products to customers in Central America and the Caribbean basin, Crowley executive Claudia Kattan-Jordan said in a prepared statement. The Togoroz, named for the national bird of El Salvador, has a capacity of 1,400 teu, an industry measurement that is equivalent to 20 feet, and includes 300 refrigerated containers. The ship is designed to transport clothing, pharmaceuticals, textiles, fresh produce and other food between the United States, El Salvador, Guatemala, Honduras and Nicaragua. Crowley launched the Quetzal, the first ship in the series in April, followed by the Copán and the Tiscapa. Each of the ships are named to honor Central American culture where Crowley has operated for more than 60 years, according to the company.
Associated Press
26-02-2025
- Business
- Associated Press
Avance Biosciences™ Registers with CLIA, Expanding Clinical Trial Testing Capabilities
HOUSTON, Feb. 26, 2025 /PRNewswire/ -- Avance Biosciences, a leading provider of high-quality analytical and bioanalytical services for the pharmaceutical industry, is pleased to announce that it has successfully registered with the Clinical Laboratory Improvement Amendments (CLIA) program. This registration allows Avance Biosciences to operate under its assigned CLIA number and offer high-complexity laboratory testing to support clinical trials, regulatory submissions, and the development of companion diagnostics for biologic drugs. By registering with CLIA, Avance Biosciences asserts that it has established the necessary infrastructure and quality systems to meet rigorous quality standards and federal regulatory requirements for laboratory testing. This commitment ensures the reliability and reproducibility of critical clinical trial data. Under this registration, the company now offers a comprehensive suite of biomarker validation, pharmacogenomics, immunogenicity testing, and other specialized assays to support clinical trials, biomarker development and validation, and diagnostic device development and validation. 'CLIA registration represents a significant step forward for Avance Biosciences as we continue to expand our support for clinical trials and biopharmaceutical development,' said Xuening Huang, CEO of Avance Biosciences. " Industry experts who have reviewed our facility have described it as one of the most well-prepared CLIA labs they have encountered, reinforcing Avance's commitment to excellence in providing high-quality, regulatory-compliant testing solutions that accelerate drug development and bring innovative therapies to patients faster.' With its CLIA registration, Avance Biosciences is positioned to support clients in the development of small molecule drugs and biologics, including mRNA therapeutics and vaccines, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), as well as gene and cell therapeutics. By ensuring compliance with CLIA standards, the company provides the clinical data necessary for regulatory approvals while maintaining the highest levels of accuracy and consistency. About Avance Biosciences Avance Biosciences is a leading provider of GLP/GMP-compliant analytical services supporting the development of biological drugs and companion diagnostics. Specializing in genomic, proteomic, immunoassay, and cell-based assay solutions, the company serves biopharmaceutical innovators with advanced testing capabilities tailored to regulatory requirements. Media Contact: Chris Hebel VP of Marketing
